Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis

Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis

In order to investigate the predictive factors related to clinical efficacy and radiographic progression at 24 weeks by looking at the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 including baseline characteristics in patients with rheumatoid arthritis (RA) treated with golim...

Full description

Bibliographic Details
Main Authors: Kanbe, Katsuaki, Chiba, Junji, Inoue, Yasuo, Taguchi, Masashi, Yabuki, Akiko
Format: Online
Language:English
Published: Libertas Academica 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337590/
id pubmed-4337590
recordtype oai_dc
spelling pubmed-43375902015-03-04 Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis Kanbe, Katsuaki Chiba, Junji Inoue, Yasuo Taguchi, Masashi Yabuki, Akiko Original Research In order to investigate the predictive factors related to clinical efficacy and radiographic progression at 24 weeks by looking at the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 including baseline characteristics in patients with rheumatoid arthritis (RA) treated with golimumab, serum concentrations of TNF-α and IL-6 were analyzed every 4 weeks up to 24 weeks in 47 patients treated with golimumab. Baseline levels of the Disease Activity Score 28 C-reactive protein (DAS28-CRP) and Simplified Disease Activity Index (SDAI) scores were also assessed. Radiographic progression using the van der Heijde-modified Sharp (vdH-S) score was assessed in 29 patients. Multiple regression analyses related to the DAS28-CRP score and delta total sharp score at 24 weeks was undertaken using the baseline characteristics of patients and serum concentrations of matrix metallo-proteinase (MMP)-3, TNF-α, and IL−6. The DAS28-CRP score and SDAI decreased significantly at 4 weeks up to 24 weeks compared with baseline. Serum levels of TNF-α were not changed significantly up to 24 weeks compared with baseline, but those of IL-6 decreased significantly at 4 weeks up to 8 weeks. Multiple regression analyses showed that disease duration and serum levels of MMP-3 were related significantly to the DAS28-CRP score at 24 weeks. Radiographic progression was related significantly to disease duration with regard to joint space narrowing and bone erosion. However, serum levels of TNF-α and IL-6 were not correlated significantly with the DAS28-CRP score and radiographic progression. These data suggest that decreasing serum levels of IL-6 significantly, MMP-3, and disease duration are predictive factors for RA activity in patients taking golimumab. Libertas Academica 2015-02-19 /pmc/articles/PMC4337590/ /pubmed/25741185 http://dx.doi.org/10.4137/CMAMD.S22155 Text en © 2015 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Kanbe, Katsuaki
Chiba, Junji
Inoue, Yasuo
Taguchi, Masashi
Yabuki, Akiko
spellingShingle Kanbe, Katsuaki
Chiba, Junji
Inoue, Yasuo
Taguchi, Masashi
Yabuki, Akiko
Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis
author_facet Kanbe, Katsuaki
Chiba, Junji
Inoue, Yasuo
Taguchi, Masashi
Yabuki, Akiko
author_sort Kanbe, Katsuaki
title Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis
title_short Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis
title_full Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis
title_fullStr Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis
title_full_unstemmed Predictive Factors Related to the Efficacy of Golimumab in Patients with Rheumatoid Arthritis
title_sort predictive factors related to the efficacy of golimumab in patients with rheumatoid arthritis
description In order to investigate the predictive factors related to clinical efficacy and radiographic progression at 24 weeks by looking at the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6 including baseline characteristics in patients with rheumatoid arthritis (RA) treated with golimumab, serum concentrations of TNF-α and IL-6 were analyzed every 4 weeks up to 24 weeks in 47 patients treated with golimumab. Baseline levels of the Disease Activity Score 28 C-reactive protein (DAS28-CRP) and Simplified Disease Activity Index (SDAI) scores were also assessed. Radiographic progression using the van der Heijde-modified Sharp (vdH-S) score was assessed in 29 patients. Multiple regression analyses related to the DAS28-CRP score and delta total sharp score at 24 weeks was undertaken using the baseline characteristics of patients and serum concentrations of matrix metallo-proteinase (MMP)-3, TNF-α, and IL−6. The DAS28-CRP score and SDAI decreased significantly at 4 weeks up to 24 weeks compared with baseline. Serum levels of TNF-α were not changed significantly up to 24 weeks compared with baseline, but those of IL-6 decreased significantly at 4 weeks up to 8 weeks. Multiple regression analyses showed that disease duration and serum levels of MMP-3 were related significantly to the DAS28-CRP score at 24 weeks. Radiographic progression was related significantly to disease duration with regard to joint space narrowing and bone erosion. However, serum levels of TNF-α and IL-6 were not correlated significantly with the DAS28-CRP score and radiographic progression. These data suggest that decreasing serum levels of IL-6 significantly, MMP-3, and disease duration are predictive factors for RA activity in patients taking golimumab.
publisher Libertas Academica
publishDate 2015
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337590/
_version_ 1613191543616700416

Similar Items